Advances in Malignant Lymphoma Conference: CME Request for Credit Survey

Thank you for attending the AACR Conference on Advances in Malignant Lymphoma. The AACR is accredited by the ACCME to provide continuing medical education for physicians. The AACR designates this live activity for a maximum of 29.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Request for Credit
To receive CME Credit you must complete the following Request for Credit Survey. A credit certificate (for physicians) or certificate of attendance (for non physician attendees) will only be issued to those who complete the survey. Your certificate will be sent by email after the survey is completed.

Question Title

* 1. Contact Information

First Name

Last Name

Question Title

* 2. Please enter your AACR ID number (If you don't have one, please leave blank)

Question Title

* 3. Address Information

Address

Address 2

City/Town

State

ZIP

Country

Question Title

* 4. Please indicate your email address

APPROVED SESSIONS WORKSHEET PDF: If you don't remember which sessions you attended, please access the following link to the Sessions Worksheet PDF: Advances in Malignant Lymphoma CME Sessions Worksheet

Question Title

* 5. Number of Credits Claimed

Question Title

* 6. Select One

Physician

Non Physician

Question Title

* 7. Which statement best describes your practice setting?

Laboratory Research only

Clinical Practice only

Clinical Practice and Laboratory Research

Administration

Other (please specify)

Question Title

* 8. Please rate your scope of knowledge in Advances in Malignant Lymphoma prior to participating in this CME activity.

	Little Knowledge	Some Knowledge	Moderate Knowledge	Above Average Knowledge	Extensive Knowledge
Knowledge Level	Knowledge Level Little Knowledge	Knowledge Level Some Knowledge	Knowledge Level Moderate Knowledge	Knowledge Level Above Average Knowledge	Knowledge Level Extensive Knowledge

Question Title

* 9. Activity included opportunity to learn interactively from faculty/participants?

	Strongly Agree	Agree	Neutral	Disagree	Strongly Disagree
Please rate	Please rate Strongly Agree	Please rate Agree	Please rate Neutral	Please rate Disagree	Please rate Strongly Disagree

Question Title

* 10. Content covered was useful and relevant to my practice?

	Strongly Agree	Agree	Neutral	Disagree	Strongly Disagree
Please rate	Please rate Strongly Agree	Please rate Agree	Please rate Neutral	Please rate Disagree	Please rate Strongly Disagree

Question Title

* 11. To what extent were the learning objectives met by this CME activity?

	Strongly Agree	Agree	Neutral	Disagree	Strongly Disagree
Articulate the potential advantages, challenges, and limitations of CAR-T cell therapy for Non-Hodgkin Lymphoma.	Articulate the potential advantages, challenges, and limitations of CAR-T cell therapy for Non-Hodgkin Lymphoma. Strongly Agree	Articulate the potential advantages, challenges, and limitations of CAR-T cell therapy for Non-Hodgkin Lymphoma. Agree	Articulate the potential advantages, challenges, and limitations of CAR-T cell therapy for Non-Hodgkin Lymphoma. Neutral	Articulate the potential advantages, challenges, and limitations of CAR-T cell therapy for Non-Hodgkin Lymphoma. Disagree	Articulate the potential advantages, challenges, and limitations of CAR-T cell therapy for Non-Hodgkin Lymphoma. Strongly Disagree
Provide an overview of the opportunities and challenges facing the implementation of liquid biopsies as an alternative to tissue biopsies for clinical decision making.	Provide an overview of the opportunities and challenges facing the implementation of liquid biopsies as an alternative to tissue biopsies for clinical decision making. Strongly Agree	Provide an overview of the opportunities and challenges facing the implementation of liquid biopsies as an alternative to tissue biopsies for clinical decision making. Agree	Provide an overview of the opportunities and challenges facing the implementation of liquid biopsies as an alternative to tissue biopsies for clinical decision making. Neutral	Provide an overview of the opportunities and challenges facing the implementation of liquid biopsies as an alternative to tissue biopsies for clinical decision making. Disagree	Provide an overview of the opportunities and challenges facing the implementation of liquid biopsies as an alternative to tissue biopsies for clinical decision making. Strongly Disagree
Explain how clonal dynamics and tumor heterogeneity affect clinical outcome.	Explain how clonal dynamics and tumor heterogeneity affect clinical outcome. Strongly Agree	Explain how clonal dynamics and tumor heterogeneity affect clinical outcome. Agree	Explain how clonal dynamics and tumor heterogeneity affect clinical outcome. Neutral	Explain how clonal dynamics and tumor heterogeneity affect clinical outcome. Disagree	Explain how clonal dynamics and tumor heterogeneity affect clinical outcome. Strongly Disagree
Evaluate the potential for lymphoma MATCH trials and provide rationale or support for this approach.	Evaluate the potential for lymphoma MATCH trials and provide rationale or support for this approach. Strongly Agree	Evaluate the potential for lymphoma MATCH trials and provide rationale or support for this approach. Agree	Evaluate the potential for lymphoma MATCH trials and provide rationale or support for this approach. Neutral	Evaluate the potential for lymphoma MATCH trials and provide rationale or support for this approach. Disagree	Evaluate the potential for lymphoma MATCH trials and provide rationale or support for this approach. Strongly Disagree

Question Title

* 12. The speakers presented sufficient scientific evidence to support the content presented?

	Strongly Agree	Agree	Neutral	Disagree	Strongly Disagree
Please rate	Please rate Strongly Agree	Please rate Agree	Please rate Neutral	Please rate Disagree	Please rate Strongly Disagree

Question Title

* 13. Meeting Presentations were free from commercial influence or bias?

	Strongly Agree	Agree	Neutral	Disagree	Strongly Disagree
Please rate	Please rate Strongly Agree	Please rate Agree	Please rate Neutral	Please rate Disagree	Please rate Strongly Disagree

Question Title

* 14. Please rate how likely you are to make changes in your practice in the following areas:

	Strongly Agree	Agree	Neutral	Disagree	Strongly Disagree
Incorporate new knowledge of the contributions of laboratory research to drug development and patient care, as well as the epidemiological implications of cancer incidence and mortality.	Incorporate new knowledge of the contributions of laboratory research to drug development and patient care, as well as the epidemiological implications of cancer incidence and mortality. Strongly Agree	Incorporate new knowledge of the contributions of laboratory research to drug development and patient care, as well as the epidemiological implications of cancer incidence and mortality. Agree	Incorporate new knowledge of the contributions of laboratory research to drug development and patient care, as well as the epidemiological implications of cancer incidence and mortality. Neutral	Incorporate new knowledge of the contributions of laboratory research to drug development and patient care, as well as the epidemiological implications of cancer incidence and mortality. Disagree	Incorporate new knowledge of the contributions of laboratory research to drug development and patient care, as well as the epidemiological implications of cancer incidence and mortality. Strongly Disagree
Incorporate critical concepts, related skills, and/or methods associated with basic cancer research into the clinical practice of oncology to aid in the detection, diagnosis, treatment, and prevention of cancer.	Incorporate critical concepts, related skills, and/or methods associated with basic cancer research into the clinical practice of oncology to aid in the detection, diagnosis, treatment, and prevention of cancer. Strongly Agree	Incorporate critical concepts, related skills, and/or methods associated with basic cancer research into the clinical practice of oncology to aid in the detection, diagnosis, treatment, and prevention of cancer. Agree	Incorporate critical concepts, related skills, and/or methods associated with basic cancer research into the clinical practice of oncology to aid in the detection, diagnosis, treatment, and prevention of cancer. Neutral	Incorporate critical concepts, related skills, and/or methods associated with basic cancer research into the clinical practice of oncology to aid in the detection, diagnosis, treatment, and prevention of cancer. Disagree	Incorporate critical concepts, related skills, and/or methods associated with basic cancer research into the clinical practice of oncology to aid in the detection, diagnosis, treatment, and prevention of cancer. Strongly Disagree
Refine clinical research design and protocols that improve patient outcomes.	Refine clinical research design and protocols that improve patient outcomes. Strongly Agree	Refine clinical research design and protocols that improve patient outcomes. Agree	Refine clinical research design and protocols that improve patient outcomes. Neutral	Refine clinical research design and protocols that improve patient outcomes. Disagree	Refine clinical research design and protocols that improve patient outcomes. Strongly Disagree
Develop new interdisciplinary collaborations to advance the progress of cancer research from “bench to bedside and back” yielding further improvements in patient outcomes.	Develop new interdisciplinary collaborations to advance the progress of cancer research from “bench to bedside and back” yielding further improvements in patient outcomes. Strongly Agree	Develop new interdisciplinary collaborations to advance the progress of cancer research from “bench to bedside and back” yielding further improvements in patient outcomes. Agree	Develop new interdisciplinary collaborations to advance the progress of cancer research from “bench to bedside and back” yielding further improvements in patient outcomes. Neutral	Develop new interdisciplinary collaborations to advance the progress of cancer research from “bench to bedside and back” yielding further improvements in patient outcomes. Disagree	Develop new interdisciplinary collaborations to advance the progress of cancer research from “bench to bedside and back” yielding further improvements in patient outcomes. Strongly Disagree

Question Title

* 15. As a result of your participation in the Advances in Malignant Lymphoma Conference, what are you going to do differently? Please indicate any changes to your practice:

Question Title

* 16. Please indicate any barriers you perceive in implementing changes to your practice (check all that apply).

Cost

Reimbursement/insurance issues

Lack of experience

Patient compliance issues

Lack of opportunity (patients)

Lack of resources (equipment)

Guidelines

Lack of administrative support

Lack of time to assess/counsel patients

No barriers

Other (please specify)

Question Title

* 17. Please rate your scope of knowledge in Advances in Malignant Lymphoma after participating in this CME activity.

	Little Knowledge	Some Knowledge	Moderate Knowledge	Above Average Knowledge	Extensive Knowledge
Knowledge Level	Knowledge Level Little Knowledge	Knowledge Level Some Knowledge	Knowledge Level Moderate Knowledge	Knowledge Level Above Average Knowledge	Knowledge Level Extensive Knowledge

Question Title

* 18. Please provide any additional comments or suggestions for use in planning future AACR CME activities.

Thank you for your participation in the Advances in Malignant Lymphoma Conference. Your Certificate will be processed soon and sent by email.